Our previous International Union of Basic and Clinical Pharmacology report on the nomenclature and classification of adenosine receptors (2011) contained a number of emerging developments with respect to this G protein-coupled receptor subfamily, including protein structure, protein oligomerization, protein diversity, and allosteric modulation by small molecules. Since then, a wealth of new data and results has been added, allowing us to explore novel concepts such as target binding kinetics and biased signaling of adenosine receptors, to examine a multitude of receptor structures and novel ligands, to gauge new pharmacology, and to evaluate clinical trials with adenosine receptor ligands. This review should therefore be considered a further update of our previous reports from 2001 and 2011.

中文翻译：

---

国际基础与临床药理学联盟。 CXII：腺苷受体：进一步更新


我们之前的国际基础和临床药理学联盟关于腺苷受体命名和分类的报告（2011）包含了有关该 G 蛋白偶联受体亚家族的许多新兴进展，包括蛋白质结构、蛋白质寡聚化、蛋白质多样性和变构小分子调节。从那时起，大量的新数据和结果被添加进来，使我们能够探索新的概念，例如靶点结合动力学和腺苷受体的偏向信号传导，检查多种受体结构和新的配体，衡量新的药理学，并评估腺苷受体配体的临床试验。因此，本次审查应被视为对我们 2001 年和 2011 年之前报告的进一步更新。